Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial.

Walter TP, Mazieres J, Otto J, Lena H, Lepage C, Smith D, Madelaine J, Gérinière L, Egenod T, El Hajbi F, Ferru A, Clément-Duchene C, Madroszyk A, Brotelle T, Bouhier-Leporrier K, Desrame J, Ghiringhelli F, Paleiron N, Khalil A, Milot L, Chevallier O, Couvelard A, Lantuejoul S, Langlais A, Morin F, Duruisseaux M, Michel P, Louvet C, Westeel V, Girard N, IFCT-FFCD-GERCOR GCO

Open source

DOI: 10.1200/jco-25-01657
Published: 2026 Apr 20
Container: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco-25-01657,
  title = {Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial.},
  author = {Walter TP and Mazieres J and Otto J and Lena H and Lepage C and Smith D and Madelaine J and Gérinière L and Egenod T and El Hajbi F and Ferru A and Clément-Duchene C and Madroszyk A and Brotelle T and Bouhier-Leporrier K and Desrame J and Ghiringhelli F and Paleiron N and Khalil A and Milot L and Chevallier O and Couvelard A and Lantuejoul S and Langlais A and Morin F and Duruisseaux M and Michel P and Louvet C and Westeel V and Girard N and IFCT-FFCD-GERCOR GCO},
  year = {2026},
  journal = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  doi = {10.1200/jco-25-01657},
  url = {https://doi.org/10.1200/jco-25-01657}
}

RIS

TY  - JOUR
TI  - Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial.
AU  - Walter TP
AU  - Mazieres J
AU  - Otto J
AU  - Lena H
AU  - Lepage C
AU  - Smith D
AU  - Madelaine J
AU  - Gérinière L
AU  - Egenod T
AU  - El Hajbi F
AU  - Ferru A
AU  - Clément-Duchene C
AU  - Madroszyk A
AU  - Brotelle T
AU  - Bouhier-Leporrier K
AU  - Desrame J
AU  - Ghiringhelli F
AU  - Paleiron N
AU  - Khalil A
AU  - Milot L
AU  - Chevallier O
AU  - Couvelard A
AU  - Lantuejoul S
AU  - Langlais A
AU  - Morin F
AU  - Duruisseaux M
AU  - Michel P
AU  - Louvet C
AU  - Westeel V
AU  - Girard N
AU  - IFCT-FFCD-GERCOR GCO
PY  - 2026
JO  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
DO  - 10.1200/jco-25-01657
UR  - https://doi.org/10.1200/jco-25-01657
ER  -

APA

TP, W., J, M., J, O., H, L., C, L., D, S., J, M., L, G., T, E., F, E. H., A, F., C, C., A, M., T, B., K, B., J, D., F, G., N, P., A, K., L, M., O, C., A, C., S, L., A, L., F, M., M, D., P, M., C, L., V, W., N, G., & GCO, I. (2026). Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. https://doi.org/10.1200/jco-25-01657

Source records

pubmed · retrieved 2026-09-26T19:37:43.285Z